2024 Sales Forecast
Unprecedented Growth on the Horizon
- Unprecedented sales growth forecast for bonyf NV in 2024.
- Compliance with European Medical Device Regulation boosts market position.
- Unique oral care products with patented formulations driving market success.
bonyf NV / Key word(s): Results Forecast/Annual Results
|
Ghent (Belgium), 10 May 2024, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), the next-generation oral comfort expert, is a Euronext Paris listed company and specializes in the development, production and marketing of oral, denture, orthodontic and wound care products, is poised for exponential growth in 2024.
Introduction
The bonyf achievement of compliance with the stringent European Medical Device Regulation (MDR) has significantly bolstered our market position and enhanced our credibility as a reliable and sustainable manufacturer.
Leveraging our compliance status and unique product offerings, nurture our new business model implemented since end 2022 whereas bonyf establishes itself a significant global player in contract manufacturing. Our contract manufacturing (or private label) sales YTD increased from 37% in 2023 towards 70% in 2024. Leading country supermarkets and international drugstores perform on long duration contracts as to ensure the sustainable sales growth since 2023.
Market
The global demand for oral hygiene products continues to soar, driven by increasing awareness of oral health and hygiene among consumers worldwide. bonyf belongs to the limited number of independent manufacturers for dental effervescent tablets in Europe and MDR certification successfully completed, we enjoy a competitive advantage in terms of market share and positioning.